Temozolomide pharma

Temozolomide is related to dacarbazine, because both must undergo biotransformation to an active metabolite, MTIC, which probably is responsible for the methylation of DNA on the 6 positionof guanine. Unlike dacarbazine, temozolomide does not require the CYP450 system for metabolic transformation, and it undergoes chemical transformation under normal physiological pH. Temozolomide also has the property of inhibiting the repair enzyme, O6-guanineDNA-alkyltransferase. A property that distinguishes temozolomide from dacarbazine is the former’s ability to cross the blood-brain barrier. Temozolomide is taken orally and has excellent oral bioavailability.he parent drug and metabolites are excreted in urine Temozolomide is taken for 5 consecutive days and repeated every 28 days.